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Abstract
Because tumors are characterized by hypoxic environments, we used a novel in vitro noninvasive magnetic reso-
nance imaging assay to examine the influence of invasive MDA-MB-231 breast cancer cells on the invasion and
migration of human dermal lymphatic microvascular endothelial cells (HMVEC-dLy) under normoxic and hypoxic
conditions. Nonmalignant immortalized MCF-12A human mammary epithelial cells instead of cancer cells or cham-
bers with HMVEC-dLy alone were used as controls for comparison. HMVEC-dLy cells were labeled with a T2 con-
trast agent (Feridex), and their invasion and migration through extracellular matrix under normoxic and hypoxic
conditions were monitored using magnetic resonance imaging. A significant increase in the invasion and migration
of HMVEC-dLy cells was detected in the presence of cancer cells, which further increased significantly under hyp-
oxic conditions. HMVEC-dLy cells formed interconnecting strands extending toward the cancer cells under nor-
moxic but not under hypoxic conditions. Following reoxygenation, these interconnecting strands, extending from
HMVEC-dLy cells toward the cancer cells, were observed. These data demonstrate the importance of hypoxia in
lymphatic endothelial cell invasion and migration through extracellular matrix in the presence of cancer cells.
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Introduction
Lymph node metastasis has been shown to significantly correlate with
the extent of tumor lymphangiogenesis in breast cancer [1–3]. De-
termining factors that influence lymphatic endothelial cell (LEC)
invasion and migration provide further understanding of lymphan-
giogenesis in tumors and lymph node metastases. It is now well es-
tablished that vascular endothelial growth factors C (VEGF-C) and
D (VEGF-D) stimulate lymphangiogenesis and play an important
role in lymphatic metastasis (reviewed by Refs. [4–9]). VEGF-C
and -D are known to induce the growth of lymphatic vessels through
the activation of VEGF receptor-3 (VEGFR-3) on the surface of
LECs [10,11]. Several studies have also demonstrated the role of
VEGF-A in lymphangiogenesis and lymphatic metastasis [12–14].
In contrast to normal tissue, a well-structured lymphatic network
has been found to be absent in tumors [15]. Tumors display abnormal
physiological environments characterized by hypoxia that primarily
arise from the abnormal and chaotic vasculature typically found in tu-
mors [16,17]. Since the discovery of the hypoxia-inducible factor and
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the presence of hypoxia response elements as transcriptional controls in
multiple genes [18], it has become increasingly evident that the phys-
iological environment, and hypoxia in particular, plays an important
role in the cancer phenotype. Here for the first time, we have investi-
gated the effect of hypoxia on the interaction between cancer cells and
LECs in a three-dimensional (3D) coculture system.
Two-dimensional (2D) and 3D in vitro assays for the quantitative
analysis of cell invasion and migration provide an opportunity to better
understand the underlying mechanisms of angiogenesis and lymphan-
giogenesis, characterize novel antiangiogenic and antilymphangiogenic
agents, and obtain insights into the interaction between cancer and en-
dothelial cells [19]. Whereas several studies have focused on the inter-
action between vascular endothelial cells and cancer cells using in vitro
systems [20,21], studies investigating the interaction between LECs
and cancer cells are relatively few [22]. The interaction between pros-
tate cancer cells and prostate LECs was recently studied using 2D and
3D in vitro coculture systems [13]. The interaction between LECs and
metastatic prostate cancer cells and their conditioned medium resulted
in prostate LECs tube formation and the migration of these cells,
which was not observed for poorly metastatic prostate cancer cells or
normal prostate epithelial cells. These data suggested that the tube for-
mation, cell migration, and proliferation were due to signaling through
VEGF-2 and not through VEGF-3 [13]. It has also been shown that
VEGF-A and VEGF-C increase cell migration and prostate lymphatic
cells’ capillary network formation in growth factor-reduced Matrigel
[13]. The interaction between LECs and malignant metastatic mela-
noma cells was also studied in vitro using a Boyden chamber assay
[23]. Melanoma cells secreted soluble factors that stimulated LEC mi-
gration and LEC-secreted chemokines that increased melanoma cell
motility. Data from a recent in vitro study on 177 samples from pri-
mary invasive breast cancer suggested that VEGF-C stimulated not
only VEGFR-3 but also α9β1 integrins on the surface of LECs, and
the latter played a role in the reorganization of the cellular actin cyto-
skeleton. This activation resulted in cell shape changes and in the for-
mation of pseudopodia-like structures [12].
We recently developed a 3D in vitro assay based on noninvasive
magnetic resonance imaging (MRI) that allows real-time imaging of
the migration and invasion of cells through a 3D extracellular matrix
(ECM) gel. We used this system to image, in real time, the migration of
human endothelial cells in response to breast cancer cells [20]. Here, we
have used this assay to understand the invasion and migration of LECs
in response to metastatic MDA-MB-231 breast cancer cells, under nor-
moxic or hypoxic conditions. Human dermal lymphatic microvascular
endothelial cells (HMVEC-dLy) were used as a model of LECs. The
studies were performed by labeling HMVEC-dLy with iron oxide nano-
particles that generate contrast in a magnetic resonance (MR) image.
Magnetic resonance imaging was used to visualize the invasion of
HMVEC-dLy toward cancer cells through a layer of Matrigel under
hypoxic or well-oxygenated conditions. The data obtained demonstrate
the importance of tumor hypoxia in modifying LEC invasion and mi-
gration. The implications of these findings in facilitating lymphatic me-
tastasis from hypoxic tumor regions are currently being investigated.
Materials and Methods
Cell Culture
Malignant metastatic human mammary epithelial MDA-MB-231
cells originally derived from the pleural effusion of a breast cancer
patient [24] were obtained from the American Type Culture Collection
(ATCC, Rockville, MD) and were grown as a monolayer in RPMI
1640 (Sigma, St. Louis, MO) medium supplemented with 9% fetal
bovine serum, 90 U/ml penicillin, and 90 mg/ml streptomycin. Im-
mortalized nonmalignant human mammary epithelial MCF-12A cells
established from MCF-12M mortal cells were obtained from ATCC
and were cultured in Dulbeco’s modified Eagle’s medium (DMEM)
Ham’s F12 medium [25] supplemented with 0.1 μg/ml cholera toxin,
10 μg/ml insulin, 0.5 μg/ml, hydrocortisone, 20 ng/ml epidermal
growth factor, 10% horse serum, 90 U/ml penicillin, and 90 mg/ml
streptomycin. Human dermal lymphatic microvascular endothelial cells
(HMVEC-dLy) obtained from Lonza Walkersville Inc. (Walkersville,
MD) were maintained in EGM-2 MV medium (Lonza Walkersville
Inc.) containing supplements provided by the supplier. Cells were
incubated at 37°C and 5% CO2. The medium was changed every 2
to 3 days. Epithelial cells and HMVEC-dLy were used for a maximum
of five passages.
Labeling of HMVEC-dLy With Iron Oxide Nanoparticles
Before the preparation of the chamber assays, HMVEC-dLy were
labeled with commercially available iron oxide nanoparticles (Feridex;
Berlex Inc., Wayne, NJ) to monitor cell migration and/or invasion by
MRI. Feridex is a Food and Drug Administration–approved widely
used T2 contrast agent consisting of a stable suspension of dextran-
coated iron oxide nanoparticles [26] with a molecular weight of ap-
proximately 400 kDa. Successful cell labeling requires the use of a
transfection reagent such as poly-l-lysine (PLL). A mixture of Feridex
and PLL produces a stable complex that provides efficient cell labeling
[27]. In this study, the labeling solution was prepared by mixing
5.45 μl of Feridex suspension (11 mg/ml total iron concentration)
and 6.75 μl (1:20 dilution) of PLL (55 ng/ml total concentration) in
EGM-2 MV medium. The mixture was gently agitated at 50 rpm
using a minirotator system (Glas-Col LLC, Terre Haute, IN) for 1 hour.
The medium of HMVEC-dLy, once 70% to 80% confluent, was re-
placed with the labeling solution, and cells were further incubated for
24 hours at 37°C and 5% CO2.
Chamber Preparation
Invasion chambers were prepared by using Millicell non–cell culture
inserts (Millipore, Billerica, MA) with a 12-mm diameter and mem-
brane pore size of 0.4 μm. Extracellular matrix gel (Sigma-Aldrich)
from Engelbreth Holm-Swarm sarcoma produced in mice was used
as an invasion barrier between HMVEC-dLy and MDA-MB-231
breast cancer cells or MCF-12 A cells (Figure 1). The inner walls
of the chambers were carefully coated with a sterile layer of paraffin
to reduce meniscus formation, thereby creating an even distribution
of the ECM gel. Before use, the ECM gel was thawed overnight at
4°C and diluted with cold DMEM to a final protein concentration
of 8.8 mg/ml. All manipulations of the ECM gel were performed
on ice. A total of 150 μl of ECM gel was added as the first layer of
invasion chamber and kept for at least 30 minutes at 37°C in the in-
cubator to polymerize. Then, 1.5 × 105 MDA-MB-231 or MCF-12A
cells resuspended in 100 μl of RPMI or DMEM Ham’s F12 medium
were slowly added, and the chamber was kept for approximately 3 to
4 hours at 37°C and 5% CO2 in the incubator. In control chambers
containing HMVEC-dLy, 100 μl of EGM-2 MV medium was added.
The second layer of ECM gel was diluted 1:1 (v/v) with cold DMEM
medium to avoid the formation of a concave interface, and 200 μl of
the diluted ECM gel was added to the chambers. The chambers were
returned to the incubator to allow gel polymerization for about 30 to
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40 minutes, and finally 1.5 × 105 Feridex-labeled HMVEC-dLy in
200 μl of EGM-2 MV medium were seeded on the second layer of
ECM gel. The chambers were incubated for an additional 24 hours in
24-well plates and hydrated with 300 μl of EGM-2 MV medium
added around each chamber, before the MRI studies. Because cell mi-
gration can be accompanied by degradation of ECM, it was important
to know the initial volume of ECM gel to quantify the intact volume.
For this purpose, several chambers were also prepared to monitor the
zero time point. In this case, instead of cells, a second layer of ECM
gel labeled with a Feridex suspension was added and the chambers
were scanned after 30 minutes of incubation at 37°C. To monitor
the degradation of ECM gel during the migration of HMVEC-dLy
toward cancer cells, we also labeled ECM gel with a gadolinium-
diethylenetriamine pentaacetic acid–bovine serum albumin (Gd-DTPA–
BSA; 60 mg/ml) complex to detect the second layer of ECM gel
from T1-weighted images.
Hypoxia Experiments
A hypoxia incubator chamber with 1% of O2 and 5% of CO2
with 37°C and 90% humidity was used for these experiments.
Two separate sets of experimental and control chambers were ex-
posed to hypoxic conditions for 24 and 48 hours. Before the exper-
iment, the chamber was calibrated, and the level of oxygen was
maintained using a gas oxygen controller (PROX Model-110; Bio-
Spherix, Ltd, Redfield, NY).
Magnetic Resonance Imaging
The migration of HMVEC-dLy toward cancer cells was monitored
using a 500-MHz (11.74 T) wide-bore MR spectrometer (Bruker
BioSpin GmbH, Rheinstetten, Germany) equipped with triple-axis
gradients. Before imaging, 15-mm custom-made MR tubes were auto-
claved and filled with sterile EGM-2 MV medium. Chambers were
gently introduced into the MR tube under sterile conditions and
allowed to settle at the bottom of the tube. Excess of medium was
removed from the tube, which was placed within a 23-mm birdcage
coil for imaging. Coronal and axial images were acquired using a T2-
weighted, multislice, spin-echo sequence with a field of view of
1.6 cm, acquisition matrix of 256 × 256, slice thickness of 0.5 mm,
TE of 60 milliseconds, and TR of 617 milliseconds. T1-weighted
images were obtained using the same sequence except with TE of
15 milliseconds and TR of 200 milliseconds. All chambers were
scanned at 24, 48, and 72 hours after seeding. Some chambers were
also scanned 120 hours after seeding. After imaging, the chambers
were returned to the 24-well plate, and the EGM-2 MV medium
was changed in each well and chamber. Axial T2-weighted MR images
were used to calculate the percent of fractional area of hypointensity.
All images were analyzed using the Image J program (National Insti-
tutes of Health, Bethesda, MD). The fractional area of hypointensity
was considered to be proportional to the number of iron oxide–labeled
HMVEC-dLy. The amount of gel degradation was estimated from
coronal images using a Canvas X program (ACD Systems International
Inc., Victoria, British Columbia, Canada) by determining changes in
the area of the ECM gel over time.
Staining for HMVEC-dLy With LYVE-1
To confirm the network formation of HMVEC-dLy attached to the
surface of ECM, cells were stained with an antibody specific for LECs
(LYVE-1 antibody; Research Diagnostics, Inc., Flanders, NJ) [28].
Cells attached to the surface of the ECM were gently washed with
PBS and incubated with 4.7 μg/ml of rabbit anti–mouse LYVE-1 anti-
body for 24 hours at 4°C. After washing with PBS, cells were incu-
bated with goat anti–rabbit Alexa Fluor 488 (Molecular Probes,
Inc., Eugene, OR) secondary antibody for 3 hours in a dark at room
temperature. Stained cells were analyzed (magnifications, ×4 and ×10)
using an optical microscope (Eclipse TS100; Nikon Instruments, Inc.,
Melville, NY).
ELISA Assay for the Quantification of VEGF-C
VEGF-C expression was quantified using a human VEGF-C quan-
tikine ELISA kit from the R&D Systems (Minneapolis, MN). Media
were collected after 48 hours incubation of 1.5 × 105 cells of MDA-
MB-231, MCF-12A, or HMVEC-dLy in their corresponding media
and from coculturing MDA-MB-231 and MCF-12A cells with
HMVEC-dLy in EGM-2 MVmedia under normoxic and hypoxic con-
ditions. The assay was carried out according to the manufacturer’s pro-
tocol. Total protein concentrations were determined using the Bio-Rad
Assay for protein quantification (Bio-Rad Laboratories, Hercules, CA).
Prussian Blue Staining
For Prussian blue staining, 5 × 104 of HMVEC-dLy in 750 μl of
EGM-2 MV medium labeled as previously described were seeded in
four-well slide chambers. Cells were fixed 24 hours later in 3%
Figure 1. Schematic view of (A) experimental chamber with MDA-MB-231 cells, (B) MCF-12A cells, and (C) HMVEC-dLy only. The top
layer represents HMVEC-dLy separated by an ECM layer fromMDA-MB-231 or MCF-12A cells that are layered at the bottom of chamber.
The arrow shows the direction of HMVEC-dLy invasion and migration.
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paraformaldehyde solution (Sigma), incubated with freshly prepared
Perl’s reagent for 30 minutes in the dark, washed three times with
PBS, and incubated for 5 minutes with nuclear fast red (Fluka, St.
Louis, MO). The presence of Feridex nanoparticles within the cell
cytoplasm was clearly seen from the Prussian blue staining of cells
using an optical microscope (Eclipse TS100, Nikon Instruments,
Inc.) as shown in Figure W1.
MTT Cell Proliferation Assay
To determine the effect of Feridex labeling as well as hypoxia on
cell viability/proliferation, 4000 HMVEC-dLy and Feridex-labeled
HMVEC-dLy in 100 μl of EGM-2 MV medium were seeded in
96-well plates and incubated under normoxic and hypoxic conditions
for 24 and 48 hours. After incubation, 10 μl of methylthiazol tet-
razolium (MTT) dye solution (ATCC Bioproducts, Manassas, VA)
was added to each plate, and cells were incubated for an additional
4 hours. A detergent reagent (100 μl) was then added to each well,
and plates were kept overnight in the dark. The absorbance was read
on a microplate reader (Dynatech MR7000; Dynatech Instrument
Inc., Carson, NV) at 550 nm. These data demonstrate that labeling
of HMVEC-dLy with Feridex had minimal effect on cells viability/
proliferation as shown in Figure W2.
Statistical Analysis
All data were analyzed and presented as mean ± SEM. P values
were determined by an unpaired Student’s t test. P < .05 was consid-
ered significant.
Results
MDA-MB-231 Cells Promote HMVEC-dLy Invasion and
Migration Under Oxygenated Conditions
The representative images shown in Figure 2A and the quantita-
tive analysis in Figure 3A demonstrate that, under well-oxygenated
conditions, the presence of MDA-MB-231 cancer cells resulted in
a significant increase of HMVEC-dLy invasion and migration toward
the cancer cells over time compared to chambers containing non-
malignant immortalized MCF-12A cells or HMVEC-dLy alone.
By 72 hours, HMVEC-dLy in the presence of MDA-MB-231 cells
were clearly detected further into the chamber (Figure 2A, 72 hours,
middle and last images). This behavior was confirmed by quantitative
analysis of axial images where significant increases in the values of
fractional area for experimental chambers containing MDA-MB-
231 cells were detected [at 72 hours, 5.33 ± 0.5% for MDA-MB-
231 cells (n = 10) compared to 0.3 ± 0.06% for MCF-12A cells
(n = 5) and 1.6 ± 0.5% for HMVEC-dLy only (n = 9)].
Hypoxia Promotes HMVEC-dLy Invasion and Migration in
the Presence of MDA-MB-231 Cells
An increase in the invasion and migration of HMVEC-dLy toward
MDA-MB-231 cancer cells (n = 8) under hypoxic conditions com-
pared to normoxic conditions was evident for comparable time points
in the MR images (Figure 2B). A large fraction of HMVEC-dLy was
detected in the first two slices by 24 hours, demonstrating the in-
creased invasion and migration of HMVEC-dLy in the presence
Figure 2. Representative MR images of three representative axial slices obtained at 24, 48, and 72 hours for chambers containing
HMVEC-dLy cocultured with MDA-MB-231 cells or MCF-12A cells, or with HMVEC-dLy only, obtained under (A) normoxic and (B) hyp-
oxic conditions. Arrows show the direction of Feridex-labeled HMVEC-dLy migration.
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of cancer cells under hypoxia even though HMVEC-dLy viability/
proliferation decreased (Figure W2). In contrast, hypoxia neither af-
fected the invasion and migration of HMVEC-dLy toward nonmalig-
nant MCF-12A cells (n = 5) nor increased the invasion and migration
of HMVEC-dLy alone (n = 5). In fact, a significant decrease of inva-
sion and migration was observed in HMVEC-dLy under hypoxic con-
ditions. These observations are reflected in the quantitative analysis
shown in Figure 3, where a significant increase in the percentage val-
ues of fractional area at 24 and 48 hours appeared for chambers con-
taining MDA-MB-231 cells but not for chambers with MCF-12A
cells or HMVEC-dLy alone.
Hypoxia Promotes ECM Gel Degradation By HMVEC-dLy in
the Presence of MDA-MB-231 Cells
To quantify the volume of intact ECM gel during HMVEC-dLy
migration and invasion, we labeled the second layer of ECM gel in
additional chambers with a Gd-DTPA–BSA complex. Representative
examples of T1-weighted coronal images of chambers with MCF-
12A cells are shown in Figure 4A. The bright area corresponds to
the intact labeled ECM gel, whereas the dark line on top of the
ECM gel is from Feridex-labeled HMVEC-dLy. Changes in the vol-
ume of gel are evident at 48 and 72 hours (arrow). The intact volume
of ECM gel was quantified as V = (π × r × S)/2, where r is the radius
of the chamber (1.39 cm) and S is the surface area of the ECM gel
(determined for each chamber from coronal slices using at least two
slices per chamber). Values of the intact ECM gel volume decreased
with time under normoxic conditions (Figure 4, B–D) irrespective of
the presence of cancer cells. Under hypoxic conditions, a significantly
higher degradation of ECM over time was observed for MDA-MB-
231 cells (Figure 4B); in contrast, there were no changes in the intact
ECM gel volume over time for chambers containing MCF-12A cells
or HMVEC-dLy alone (Figure 4, C and D).
MDA-MB-231 Cells Promote the Aggregation and Formation
of Protrusions of HMVEC-dLy Under Normoxic Conditions
Light microscopy of cells near the surface of the ECM gel showed
the formation of aggregates of HMVEC-dLy with extensive protru-
sions in chambers containing MDA-MB-231 cells (Figure 5A). Sev-
eral HMVEC-dLy were observed to form aggregates and protrusions
that connected to the MDA-MB-231 cells. HMVEC-dLy in cham-
bers with MCF-12A cells or HMVEC-dLy alone exhibited a tendency
to form cell clusters at 72 hours, but no protrusions were observed
(Figure 5A). Immunofluorescent staining of HMVEC-dLy with
LYVE-1 antibody clearly showed evidence of aggregates and protrusion
formation under normoxic conditions (Figure 5A).
Hypoxia Inhibits HMVEC-dLy Cell Protrusions that
Form After Reoxygenation
HMVEC-dLy protrusions evident in chambers containing MDA-
MB-231 cancer cells under normoxic conditions were not apparent
when these chambers were maintained under continuous hypoxia for
24 or 48 hours (data not shown). When these chambers were reox-
ygenated, by 50 hours of exposure to normoxia, HMVEC-dLy again
displayed these protrusions-like structures in the presence of cancer
cells (Figure 5B).
VEGF-C Correlates With Formation of
Protrusions By HMVEC-dLy
To determine the role of VEGF-C expression in HMVEC-dLy mi-
gration, and aggregate and protrusion formation, we performed
ELISA for VEGF-C secreted by MDA-MB-231, MCF-12A, and
HMVEC-dLy cells alone or MDA-MB-231 or MCF-12A cells cocul-
tured with HMVEC-dLy in EGM-2 MV medium. Consistent with
the migratory response of HMVEC-dLy, MDA-MB-231 cells secreted
the highest amount of VEGF-C (Figure 6A). In addition, in coculture,
HMVEC-dLy cells formed aggregates with tube-like structures
(Figure 6B, arrows) in the presence of MDA-MB-231, but not in
the presence of MCF-12A cells. Hypoxia, however, did not significantly
increase VEGF-C secretion by MDA-MB-231 cells, but instead re-
sulted in a decrease of VEGF-C (Figure 6A).
Discussion
The presence of metastatic MDA-MB-231 breast cancer cells signif-
icantly increased the invasion and migration of HMVEC-dLy under
Figure 3. Quantitative analysis of fractional area occupied by labeled HMVEC-dLy at 24, 48, and 72 hours under normoxic and hypoxic
conditions. Chambers with (A) MDA-MB-231 cells, (B) MCF-12A cells, and (C) HMVEC-dLy only, where *P< .0005, **P< .006, ***P< .05.
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normoxic conditions. These observations are consistent with the sig-
nificantly higher VEGF-C levels secreted by the MDA-MB-231 cells
compared to MCF-12A cells or HMVEC-dLy. Previous studies with
prostate cancer and melanoma cell lines have demonstrated the ability
of cancer cells to secrete paracrine factors that attract LECs [12,23].
HMVEC-dLy alone also migrated through ECM under normoxic
conditions but to a significantly lesser extent than in the presence of
MDA-MB-231 cancer cells. In contrast, when nonmalignant MCF-
12A cells were present, there was hardly any migration of HMVEC-
dLy suggesting that MCF-12A cells actively reduced the migration of
HMVEC-dLy. In the presence of MDA-MB-231 breast cancer cells,
HMVEC-dLy formed interconnecting strands extending toward the
cancer cells. Some of the cells formed cell aggregates that were con-
nected by extensive protrusion-like structures. These structures were
not observed in chambers with MCF-12A cells or with HMVEC-
dLy alone. Similarly, these structures were not evident under hypoxic
conditions but were clearly observed with reoxygenation.
Under hypoxic conditions, the invasion and migration of HMVEC-
dLy was significantly higher than under normoxic conditions. These
data demonstrate the important role of hypoxia in enhancing the in-
vasion and migration of LECs toward metastatic breast cancer cells.
In contrast, hypoxia did not affect the invasion and migration of
HMVEC-dLy either alone or in the presence of nonmalignant MCF-
12A cells. In fact, the invasion and migration of HMVEC-dLy alone
was significantly reduced under hypoxic conditions, which may partly
be due to the reduction of HMVEC-dLy viability/proliferation under
hypoxic conditions. A previous study has also detected a reduction in
LEC proliferation, but not viability, with hypoxia [29]. Rat LECs have
also been observed to undergo modification in the organization of actin
cytoskeleton and intercellular junctions under hypoxia resulting in de-
creased cell migration [30]. Because the interconnecting strands and pro-
trusions were not evident under hypoxic conditions in our study, it is
not likely that the formation of these pseudopodia were responsible for
the increased invasion and migration of HMVEC-dLy toward MDA-
MB-231 breast cancer cells under hypoxia. VEGF-C secreted by
MDA-MB-231 cells tended to be lower under hypoxic conditions,
and the absence of the HMVEC-dLy pseudopodia under hypoxic con-
ditions may be related to lower VEGF-C levels.
The degradation and remodeling of ECM initiated by chemo-
attractants is essential in cell migration [31]. The development of
lymphangiogenesis also depends on the structure, composition, and
mechanical properties of ECM [22,32,33]. In this 3D in vitro MRI
assay, we used commercially available ECM gel as a barrier between
HMVEC-dLy and MDA-MB-231 or MCF-12A cells and examined
the interaction between HMVEC-dLy cells and ECM gel in the pres-
ence or absence of cancer cells. By determining the volume of intact
ECM, we were able to determine the degradation of ECM under the
different conditions investigated. Our data demonstrate that ECM
Figure 4. (A) A panel of representative slices of coronal MR images at 24, 48, and 72 hours of a chamber with MCF-12A cells maintained
under normoxic conditions; Gd-DTPA–BSA–labeled ECM gel was used for quantification of the intact volume of ECM gel during the
invasion and migration of HMVEC-dLy cells. Chambers with (B) MDA-MB-231 cells, (C) MCF-12A cells, and (D) HMVEC-dLy only, where
*P = .0001, **P < .004, ***P < .05.
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degradation most likely played a role in the increased invasion and
migration of HMVEC-dLy toward cancer cells under hypoxic condi-
tions. Whereas there was some degradation of ECM with time in
chambers with MCF-12A cells or HMVEC-dLy alone under oxygen-
ated conditions, hypoxia resulted in a loss of degradation of ECM in
these chambers. Inhibition of ECM degradation, together with an
induction of LEC adhesive properties, under hypoxia has also been
previously observed by Irigoyen et al. [29].
As mentioned earlier, we did not detect a significant increase of
VEGF-C under hypoxic conditions in the current study. Whereas hyp-
oxia is a potent inducer of VEGF-A, the few studies performed on
other members of the VEGF family suggest that they are not induc-
ible by hypoxia [29,34]. However, in a recent study, Schoppmann
et al. [35] have found a significant correlation between VEGF-C
and hypoxia-inducible factor 1α in 119 cases of lymph node–positive
invasive breast cancer. The VEGF family is currently known to consist
of six growth factors highly specific for endothelial cells. These are
VEGF-A (or VEGF), -B, -C, -D, -E, and the placenta growth factor
(PIGF) [10,11,36]. VEGF-A is primarily angiogenic but may also
be lymphangiogenic and binds to its receptors VEGFR-1 (Flt-1) and
VEGFR-2 (KDR/Flk1). VEGF-C was discovered as the ligand of the
receptor fms–like tyrosine kinase, Flt4, or VEGFR-3, and it is now
known to demonstrate lymphangiogenic activity. Lymphangiogenic
activity was also reported for VEGF-D signaling through the same
VEGFR-3 receptor. It is possible that the increase in HMVEC-dLy inva-
sion and migration in response to hypoxia in the presence of MDA-MB-
231 cells may have been mediated by an increase in VEGF-A.
Other factors may have also promoted HMVEC-dLy migration in
the presence of MDA-MB-231 cancer cells under hypoxic condi-
tions. Candidates include stromal-derived factor-1 (SDF-1/CXCL12)
and its receptor CXCR4 that are expressed in human breast carci-
noma [37] and are induced by hypoxia [38] and contribute to the
cell migration [29]. CXCL12 was found to be strongly expressed
in LEC exposed to 24 hours of hypoxia; the migration of cancer cells
toward LEC was inhibited by blocking CXCR4 showing the impor-
tance of this signaling pathway [29]. PIGF, a growth factor of the
Figure 5. (A) White light and corresponding LYVE-1–stained fluorescent images of experimental chambers with MDA-MB-231 cells,
MCF-12A cells, and chambers with HMVEC-dLy only after incubation for 72 hours in normoxic conditions. (B) White light and
corresponding LYVE-1–stained fluorescent images of experimental chambers with MDA-MB-231 cells after 24 hours of hypoxia fol-
lowed by 50 hours of normoxia (shown on left) and 48 hours of hypoxia followed by 50 hours of normoxia (shown on right).
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VEGF family, was found to be moderately expressed in MDA-MB-
231 cells [39], and its expression was induced by hypoxia in fibro-
blasts and human choriocarcinoma cells [40]. It was recently shown
that an antibody against PIGF inhibited lymphangiogenesis and de-
creased VEGF-C [41]. The increased migration of HMVEC-dLy to-
ward MDA-MB-231 cells under hypoxia observed by us may have
been mediated, in part, through increased PIGF.
In conclusion, the use of a 3D in vitro assay system revealed the
importance of hypoxia in LEC invasion and migration through ECM
in the presence of metastatic breast cancer cells and provided further
insights into LEC invasion and migration. Future studies charac-
terizing the hypoxic response of HMVEC-dLy invasion and migra-
tion in the presence of cancer cells with downregulated VEGF-A, -C,
and -D will provide additional understanding of the observations
made here. Additional studies with a range of metastatic and non-
metastatic breast cancer cell lines should confirm the role of hypoxia
in LEC invasion and migration. In vivo studies using tumor models
genetically engineered to report on hypoxia [42] should provide fur-
ther understanding of the presence of LECs in hypoxic regions and
their role in lymphatic metastasis.
Supplementary Materials
The presence of Feridex nanoparticles within the cell cytoplasm
was confirmed by Prussian blue staining (Figure W1).
Hypoxia Influences the HMVEC-dLy Viability
We used the MTT cell viability/proliferation assay to determine
whether hypoxic conditions affect HMVEC-dLy and Feridex-labeled
HMVEC-dLy viability at 24 and 48 hours under normoxic or hypoxic
conditions (Figure W2). Viability values under hypoxic conditions
were normalized to the corresponding values under normoxic condi-
tions at 24 and 48 hours. Cell labeling with Feridex did not affect cell
viability under normoxic conditions at the 24-hour time point. The
viability of HMVEC-dLy without labeling and after labeling with
Feridex was reduced by 17% and 10% correspondingly after 24 hours
of exposure to hypoxia. The exposure of cells to hypoxic conditions for
48 hours reduced HMVEC-dLy viability by 36% and 28% when cells
were labeled with Feridex relative to the normoxic control.
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Figure W1. Prussian blue staining of HMVEC-dLy labeled with
Feridex nanoparticles.
Figure W2. Effect of Feridex labeling and hypoxia on HMVEC-dLy
viability/proliferation. *P < .0001, **P < .03.
